Araim Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel small molecule therapies for Alzheimer's disease and other neurodegenerative disorders. The company specializes in targeting the ATF6 (Activating Transcription Factor 6) branch of the unfolded protein response (UPR), a cellular signaling pathway that plays a critical role in endoplasmic reticulum (ER) stress response[1].
A-966084 is Araim Pharmaceuticals' lead clinical candidate, a small molecule activator of ATF6:
| Attribute | Details |
|---|---|
| Target | ATF6 (Activating Transcription Factor 6) |
| Mechanism | Direct activation of ATF6 transcription factor |
| Indication | Alzheimer's disease |
| Phase | Phase 1 |
| Status | Clinical development ongoing |
The ATF6 branch of the UPR is primarily adaptive, driving expression of:
By activating ATF6, A-966084 enhances the cell's natural protective response to ER stress, which is elevated in Alzheimer's disease brains[2].
ER stress is an early event in AD pathogenesis:
ATF6 is an ER transmembrane protein that senses ER stress:
Araim competes with other companies developing UPR modulators:
| Company | Program | Mechanism | Indication |
|---|---|---|---|
| Biogen | BIIB110 | IRE1-XBP1 pathway | AD |
| Biogen | BIIB094 | PERK inhibitor | AD |
| QurAlis | QRL-101 | IRE1 inhibitor | ALS |
| Cyclo Therapeutics | Trap-Lect | BiP modulator | AD |
ATF6 as a therapeutic target for Alzheimer's disease. Scientific Reports. 2023. ↩︎